A combination of PPARα agonist fenofibrate and UDCA could decrease serum AST, ALT, ALP, γ-glutamyl transpeptidase, and TG in PBC (classic intrahepatic cholestasis) patients, who are not responsive to UDCA alone (Ghonem and Boyer, 2013). This evidence concerns the gene GPT and primary biliary cholangitis.